Search

Author/Creator Shu, Cathye

1. Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. Issue 6 (28th May 2020)

Authors:
Zhu, Yaowei; Xu, Yan; Zhuang, Yanli; Piantone, Alexa; Shu, Cathye; Chen, Dion; Zhou, Honghui; Xu, Zhenhua; Sharma, Amarnath
Journal:
Clinical and translational science
Issue:
Volume 13:Issue 6(2020)
Page Start:
1217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Issue 11 (7th July 2022)

Authors:
van Vollenhoven, Ronald F; Kalunian, Kenneth C; Dörner, Thomas; Hahn, Bevra H; Tanaka, Yoshiya; Gordon, Robert M; Shu, Cathye; Fei, Kaiyin; Gao, Sheng; Seridi, Loqmane; Gallagher, Patrick; Lo, Kim Hung; Berry, Pamela; Zuraw, Qing C
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 11(2022)
Page Start:
1556
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis. Issue 12 (14th June 2020)

Authors:
Nnane, Ivo; Frederick, Bart; Yao, Zhenling; Raible, Donald; Shu, Cathye; Badorrek, Philipp; van den Boer, Maarten; Branigan, Patrick; Duffy, Karen; Baribaud, Frédéric; Fink, Damien; Yang, Tong‐Yuan; Xu, Zhenhua
Journal:
British journal of clinical pharmacology
Issue:
Volume 86:Issue 12(2020)
Page Start:
2507
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗